NRG Oncology Network Group Operations Center - BIQSFP

NRG 肿瘤网络集团运营中心 - BIQSFP

• 批准号: 10322236
• 负责人: WALTER J. CURRAN
• 金额: $ 94.69万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10322236
• 关键词: Adult; African; Area; Awareness; Brain Neoplasms; Breast; Cancer Patient; Cancer Therapy Evaluation Program; Clinical Research; Clinical Trials; Development; Disease; Enrollment; Ensure; Gender; Goals; Gynecologic; Head and Neck Cancer; Hispanics; International; Latino; Lead; Leadership; Locally Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Manuscripts; National Clinical Trials Network; Non-Hematologic Malignancy; Oncology; Patients; Peer Review; Positioning Attribute; Precision medicine trial; Protocols documentation; Publishing; Research; Scientific Advances and Accomplishments; Site; Time; Translational Research; advanced disease; advanced prostate cancer; clinically relevant; cohort; design; improved; interest; malignant breast neoplasm; member; multidisciplinary; oncology trial; operation; patient population; sarcoma

NRG Overall Component Abstract NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-specific malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP- supported NRG trials open for enrollment during this period, representing 34% of the open NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of African descent and 8.0% as Latino or Hispanic. There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published abstracts during this period, of which at least 52 contain practice-changing or practice-defining observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site committees, all with internationally recognized multi-disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.

NRG 总体组件摘要 NRG 肿瘤学 (NRG) 在改善患者生活的目标方面取得了重大进展 通过其临床和转化研究患有某些非血液恶性肿瘤的成年人 努力。 NRG 定义的感兴趣的患者群体 - 患有特定性别恶性肿瘤的患者 和/或患有局部或局部晚期疾病的患者在 NCTN 中是独一无二的， 构成了一个庞大且相对而言研究不足的癌症患者群体。定位为 NCTN 的领先研究组织，进行招募多个患者队列的试验，NRG 的产品组合 重点关注妇科癌症、原发性或继发性脑肿瘤、头颈部肿瘤患者 癌症，或局部或局部晚期前列腺癌以及乳腺癌、肺癌、 胃肠道癌、膀胱癌或肉瘤。在这些和其他领域 NRG 积极 与其他 NCTN 团体合作，努力提高人们的认识和 参与所有 NCTN 试验。 NRG 迄今为止的研究成就非同寻常。已有 87 个 CTEP- 支持的 NRG 试验在此期间开放注册，占开放注册的 34% NCTN 成人试验。 2014年3月1日至2017年8月31日期间，NRG成员 10,840 名患者参加了 NRG 主导的试验，3,199 名患者参加了其他 NCTN 主导的试验 网络小组，以及另外 1,906 名患者参加 NCTN 精准医学试验 总共 15,945 个条目。在 NCTN 治疗登记总数 48,056 人中，NRG 的贡献 占总参赛人数的 33%，是五个 NCTN 中参赛人数最多的 组。截至目前，在美国站点参加 NRG 试验的患者中，12.7% 的患者进行了自我鉴定 非洲裔和 8.0% 为拉丁裔或西班牙裔。 NRG 已发表或出版了 302 篇经过同行评审的手稿，其中 365 篇已发表 这一时期的摘要，其中至少 52 篇包含改变实践或定义实践的摘要 观察。为了成功实现其雄心勃勃的目标，NRG 拥有七个癌症疾病站点 委员会，所有委员会均具有国际公认的多学科领导力，并且均具有强大的 NRG 九个科学核心委员会的联络代表。还有其他四个 协议制定委员会和五个管理委员会，全部旨在领导和 支持小组研究的关键领域。 NRG 的组织方式使得必要的 运营效率和内部同行审查是为了克服开展工作的障碍 广泛的具有科学重要性和相关性的临床试验组合，并确保适当的 参加这些试验。